The Growth-Inhibitory Effects of Dexamethasone on Renal Cell Carcinoma In Vivo and In Vitro

REFERENCES

• Motzer R. J., Russo P. Systemic therapy for renal cell carcinoma. J. Urol. 2000; 163: 408–417
   PubMed Web of Science ®Google Scholar
• Pizzocaro G., Piva L., Colavita M., Ferri S., Artusi R., Boracchi P., Parmian G., Marubini E. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J. Clin. Oncol. 2001; 19: 425–431
   PubMed Web of Science ®Google Scholar
• Clark J. I., Atkins M. B., Urba W. J., Creech S., Figlin R. A., Dutcher J. P., Flaherty L., Sosman J. A., Logan T. F., White R., Weis G. R., Redman B. G., Tretter C. P., McDermott D., Smith J. W., Gordon M. S., Margolin K. A. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J. Clin. Oncol. 2003; 21: 3133–3140
   PubMed Web of Science ®Google Scholar
• Yagoda A., Abi-Rached B., Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983–1993. Semin. Oncol. 1995; 22: 42–60
   PubMed Web of Science ®Google Scholar
• Mizutani Y., Bonavida B., Koishihara Y., Akamatsu K., Ohsugi Y., Yoshida O. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res. 1995; 55: 590–596
   PubMed Web of Science ®Google Scholar
• Motzer R. J., Michaelson M. D., Redman B. G., Hudes G. R., Wilding G., Figlin R. A., Ginsberg M. S., Kim S. T., Baum C. M., DePrimo S. E., Li J. Z., Bello C. L., Theuer C. P., George D. J., Rini B. I. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2006; 24: 16–24
   PubMed Web of Science ®Google Scholar
• Miki S., Iwano M., Miki Y., Yamamoto M., Tang B., Yokokawa K., Sonoda T., Hirano T., Kishimoto T. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett. 1989; 250: 607–610
   PubMed Web of Science ®Google Scholar
• Blay J. Y., Negrier S., Combaret V., Attali S., Goillot E., Merrouche Y., Mercatello A., Ravault A., Tourani J. M., Moskovtchenko J. F., Phillip T., Favrot M. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 1992; 52: 3317–3322
   PubMed Web of Science ®Google Scholar
• De Bosscher K., Vanden Berghe W., Vermeulen L., Plaisance S., Boone E., Haegeman G. Glucocorticoids repress NF-kappaB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. Proc. Natl. Sci. USA 2000; 97: 3919–3924
   PubMed Web of Science ®Google Scholar
• Oya M., Takayanagi A., Horiguchi A., Mizuno R., Ohtsubo M., Marumo K., Shimizu N., Murai M. Increased nuclear factor-kappa B activation is related to the tumor development of renal cell carcinoma. Carcinogenesis 2003; 24: 377–384
   PubMed Web of Science ®Google Scholar
• Matsuda M., Osafune M., Nakano E., Kotake T., Sonoda T., Watanabe S., Hada T., Okochi T., Higashino K., Yamamura Y., Abe T. Characterization of an established cell line from human renal carcinoma. Cancer Res. 1979; 39: 4694–4699
   PubMed Web of Science ®Google Scholar
• Nakano E., Tada Y., Fujioka H., Matsuda M., Osafune M., Kotake T., Sato B., Takaha M., Sonoda T. Hormone receptor in renal cell carcinoma and correlation with clinical response to endocrine therapy. J. Urol. 1984; 132: 240–245
   PubMed Web of Science ®Google Scholar
• Coleman R. E. Glucocorticoids in cancer therapy. Biotherapy 1992; 4: 37–44
   PubMedGoogle Scholar
• Nishimura K., Nonomura N., Satoh E., Harada Y., Nakayama M., Tokizane T., Fukui T., Ono Y., Inoue H., Shin M., Tsujimoto Y., Takayama H., Aozasa K., Okuyama A. Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J. Natl. Cancer Inst. 2001; 93: 1739–1746
   Google Scholar
• Nishimura K., Nonomura N., Yasunaga Y., Takaha N., Inoue H., Sugao H., Yamaguchi S., Ukimura O., Miki T., Okuyama A. Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer 2000; 89: 2570–2576
   PubMed Web of Science ®Google Scholar
• Takenawa J., Kaneko Y., Okumura K., Yoshida O., Nakayama H., Fujita J. Inhibitory effect of dexamethasone and progesterone in vitro on proliferation of human renal cell carcinomas and effects on expression of interleukin-6 or interleukin-6 receptor. J. Urol. 1995; 153: 858–862
   PubMed Web of Science ®Google Scholar
• Alberti L., Thomachot M. C., Bachelot T., Menetrier-Caux C., Puisieux I., Blay J. Y. IL-6 as an intracrine growth factor for renal carcinoma cell lines. Int. J. Cancer 2004; 111: 653–661
   PubMed Web of Science ®Google Scholar
• Blay J. Y., Rossi J. F., Wijdenes J., Menetrier-Caux C., Schemann S., Negrier S., Philip T., Favrot M. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int. J. Cancer 1997; 72: 424–430
   PubMed Web of Science ®Google Scholar
• Iwai A., Fujii Y., Kawakami S., Takazawa R., Kageyama Y., Yoshida M. A., Kihara K. Down-regulation of vascular endothelial growth factor in renal cell carcinoma cells by glucocorticoids. Mol. Cell Endocrinol. 2004; 226: 11–17
   PubMed Web of Science ®Google Scholar